Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter...

Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third
Quarter Results of Fiscal Year 2008

WEIFANG, Shandong, China, May 8 /Xinhua-PRNewswire-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or
"the Company"), a leading manufacturer and distributor of high-quality,
pharmaceutical grade glucose products in China and glucose and starch products
that serve as raw materials for food, beverage and industrial production,
today announced that it will conduct a conference call at 9:00 a.m. Eastern
Time on Friday, May 16, 2008 to discuss the third quarter results of fiscal
year 2008.
Shengtai Pharmaceutical's Chief Financial Officer, Ms. Melody Shi will be
participating in the conference call. The Company plans to make an earnings
announcement prior to the call.
To participate in the live conference call, please dial the following
number five to ten minutes prior to the scheduled conference call time: 800-
688-0796. International callers should dial 617-614-4070. When prompted by
the operator, mention Conference Passcode 502 870 72.
If you are unable to participate in the call at this time, a replay will
be available for 14 days starting on Friday, May 16 at 11:00 a.m. Eastern
Time.
To access the replay, dial 888-286-8010, international callers should dial
617-801-6888, and enter the passcode 924 807 90.
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai
Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating
company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading
manufacturer and supplier of glucose products, which include pharmaceutical
grade glucose used for medical purposes, and glucose and cornstarch products
for the food and beverage industry and for industrial production in China. For
more information about Shengtai Pharmaceutical, Inc. please visit
www.shengtaipharmaceutical.com .
Safe Harbor Statement
Safe Harbor Statement Under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral statements made by
the Company, constitute forward-looking statements for purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of 1995.
These statements include, without limitation, statements regarding our ability
to prepare the company for growth, the Company's planned capacity expansion in
2008 and predictions and guidance relating to the Company's future financial
performance. We have based these forward-looking statements largely on our
current expectations and projections about future events and financial trends
that we believe may affect our financial condition, results of operations,
business strategy and financial needs but they involve risks and uncertainties
that could cause actual results to differ materially from those in the
forward-looking statements, which may include, but are not limited to, such
factors as unanticipated changes in product demand especially in the
pharmaceutical industry, pricing and demand trends for the Company's products,
changes to government regulations, risk associated with operation of the
Company's new facilities, risk associated with large scale implementation of
the company's business plan, the ability to attract new customers, ability to
increase its product's applications, cost of raw materials, downturns in the
Chinese economy, and other information detailed from time to time in the
Company's filings and future filings with the United States Securities and
Exchange Commission. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements herein and are cautioned not to
place undue reliance on such forward-looking statements, which are qualified
in their entirety by this cautionary statement. The forward-looking
statements made herein speak only as of the date of this press release and the
Company undertakes no duty to update any forward-looking statement to conform
the statement to actual results or changes in the company's expectations.
For more information, please contact:

Company Contact:
Ms. Melody Shi
CFO
Shengtai Pharmaceutical, Inc.
Tel: +1-949-468-7078
Email: shengtaicfo@hotmail.com

Investor Relations Contact:
Mr. Crocker Coulson
President
CCG Elite Investor Relations
Tel: +1-646-213-1915 (NY Office)
Email: crocker.coulson@ccgir.com
Web: www.ccgelite.com

SOURCE Shengtai Pharmaceutical, Inc.

Company Contact - Ms. Melody Shi, CFO of Shengtai Pharmaceutical, Inc.,
+1-949-468-7078, or shengtaicfo@hotmail.com; or Investor Relations Contact,
Mr. Crocker Coulson, President of CCG Elite Investor Relations,
+1-646-213-1915 (NY Office), or crocker.coulson@ccgir.com, for Shengtai
Pharmaceutical, Inc.